This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2008 Oct;26(8):757-68.

doi: 10.1080/07357900801971040.

Anti-epidermal growth factor receptor strategies for advanced breast cancer

Susana M Campos¹

Affiliations

PMID: 18853311
DOI: 10.1080/07357900801971040

Review

Anti-epidermal growth factor receptor strategies for advanced breast cancer

Susana M Campos. Cancer Invest. 2008 Oct.

. 2008 Oct;26(8):757-68.

doi: 10.1080/07357900801971040.

Author

Susana M Campos¹

Affiliation

¹ Department of Breast and Gynecology, Dana Farber Cancer Institute, Harvard University, Boston, Massachusetts, USA.

PMID: 18853311
DOI: 10.1080/07357900801971040

No abstract available

PubMed Disclaimer

Similar articles

Update on HER-kinase-directed therapy in prostate cancer.
Gross ME, Jo S, Agus DB. Gross ME, et al. Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Clin Adv Hematol Oncol. 2004. PMID: 16163160 Review.
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A, Rojo F, Rovira A, Albanell J. Dalmases A, et al. Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27. Med Clin (Barc). 2013. PMID: 23809407 Review. Spanish. No abstract available.
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB, Hynes NE, Lane HA. Motoyama AB, et al. Cancer Res. 2002 Jun 1;62(11):3151-8. Cancer Res. 2002. PMID: 12036928
Foreword.
Chen HX, Cleck JN, Coelho R, Dancey JE. Chen HX, et al. Curr Probl Cancer. 2009 Jul-Aug;33(4):244. doi: 10.1016/j.currproblcancer.2009.10.001. Curr Probl Cancer. 2009. PMID: 20082841 No abstract available.
ErbB/HER receptor family in breast cancer--the more we search the more we learn.
Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Karamouzis MV, et al. Ann Oncol. 2008 May;19(5):1020-1. doi: 10.1093/annonc/mdn061. Epub 2008 Mar 19. Ann Oncol. 2008. PMID: 18356136 No abstract available.

See all similar articles

Cited by

Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Wang YX, Gao JX, Wang XY, Zhang L, Liu CM. Wang YX, et al. Tumour Biol. 2012 Aug;33(4):957-66. doi: 10.1007/s13277-012-0324-4. Epub 2012 Jan 18. Tumour Biol. 2012. PMID: 22252523
ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.
Chen JQ, Russo J. Chen JQ, et al. Biochim Biophys Acta. 2009 Dec;1796(2):162-75. doi: 10.1016/j.bbcan.2009.06.003. Epub 2009 Jun 13. Biochim Biophys Acta. 2009. PMID: 19527773 Free PMC article. Review.
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Campos SM, et al. Int J Clin Oncol. 2010 Aug;15(4):390-8. doi: 10.1007/s10147-010-0073-6. Epub 2010 Apr 20. Int J Clin Oncol. 2010. PMID: 20405155 Clinical Trial.
Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T, Wang Y, Zhao ZJ, Gu H. Yuan T, et al. J Biol Chem. 2010 May 14;285(20):14861-14870. doi: 10.1074/jbc.M109.099879. Epub 2010 Mar 24. J Biol Chem. 2010. PMID: 20335174 Free PMC article.
GPR54 (KISS1R) transactivates EGFR to promote breast cancer cell invasiveness.
Zajac M, Law J, Cvetkovic DD, Pampillo M, McColl L, Pape C, Di Guglielmo GM, Postovit LM, Babwah AV, Bhattacharya M. Zajac M, et al. PLoS One. 2011;6(6):e21599. doi: 10.1371/journal.pone.0021599. Epub 2011 Jun 28. PLoS One. 2011. PMID: 21738726 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal